1. Clinical Overview
L-Ornithine L-Aspartate (LOLA) is a stable salt of two amino acids, L-Ornithine and L-Aspartate. It is a key hepatoprotective and detoxifying agent primarily used in the management of hepatic encephalopathy (HE) and hyperammonemia. It works by enhancing the urea cycle and glutamine synthesis in the liver and skeletal muscle, facilitating the detoxification and excretion of ammonia. In the Indian context, it is a cornerstone therapy for acute and chronic liver disease complications, widely available in both hospital and outpatient settings.
| Onset | Duration | Bioavailability |
|---|---|---|
| Within 1-2 hours after oral administration; significant reduction in blood ammonia levels typically observed within 24-48 hours of initiating therapy. | Approximately 6-8 hours per dose, necessitating multiple daily doses for sustained ammonia-lowering effect. | Not fully established for the salt form; however, its constituent amino acids are absorbed via active transport in the small intestine. Systemic bioavailability is considered moderate. |
2. Mechanism of Action
L-Ornithine L-Aspartate exerts its therapeutic effect through two primary, interconnected pathways: 1) Enhancement of the Urea Cycle: L-Ornithine is a direct substrate for the enzyme ornithine transcarbamylase (OTC), acting as a catalyst to increase the conversion of ammonia to urea in periportal hepatocytes. 2) Promotion of Glutamine Synthesis: L-Aspartate, along with L-Ornithine, provides substrates for the enzyme glutamine synthetase, which is active in perivenous hepatocytes and skeletal muscle. This enzyme converts ammonia and glutamate into non-toxic glutamine, providing an alternative and muscle-based pathway for ammonia detoxification, especially when the urea cycle is compromised.
3. Indications & Uses
- Treatment and prevention of Hepatic Encephalopathy (Overt and Minimal) in patients with cirrhosis
- Management of hyperammonemia secondary to liver dysfunction
- Supportive therapy in acute and chronic hepatitis
- Alcoholic liver disease with hyperammonemia
4. Dosage & Administration
Adult Dosage: Oral: 1 sachet (3gm) dissolved in a glass of water or juice, 2-3 times daily. Injectable: 10-20 gm/day by slow IV infusion, diluted in 500 mL of infusion fluid, as per hospital protocol.
Administration: Take orally after meals to improve gastrointestinal tolerance. Dissolve the entire content of the sachet completely in 150-200 mL of water or a non-alcoholic, non-carbonated beverage. Consume immediately after preparation. For IV use, must be administered as a slow infusion over 4-6 hours to avoid nausea and vomiting.
5. Side Effects
Common side effects may include:
- Nausea
- Gastrointestinal discomfort
- Vomiting (especially with rapid oral intake or high doses)
- Diarrhoea or loose stools
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Potassium-Sparing Diuretics (Spironolactone, Amiloride) | Increased risk of hyperkalaemia due to additive effects on potassium levels. | Major |
| Potassium Supplements / Salt Substitutes | Increased risk of hyperkalaemia. | Major |
| Corticosteroids (e.g., Prednisolone) | May counteract potassium-lowering effects, potentially increasing hyperkalaemia risk. | Moderate |
| Lactulose | Synergistic effect in lowering blood ammonia. No adverse pharmacokinetic interaction. | Beneficial |
| Rifaximin | Synergistic effect. Used together as standard of care for HE. | Beneficial |
7. Patient Counselling
- DO take the medication exactly as prescribed, usually after meals.
- DO dissolve the powder completely in water or juice as directed.
- DO inform all your doctors about all medications you are taking, including OTC drugs and supplements.
- DONT stop taking the medication abruptly without consulting your doctor, even if you feel better.
- DONT consume alcohol while on this medication.
- DONT use the medication if you have severe kidney problems.
8. Toxicology & Storage
Overdose: Symptoms are primarily extensions of side effects: severe nausea, vomiting, diarrhoea, gastrointestinal cramps, and potential electrolyte disturbances (hyperkalaemia, metabolic alkalosis).
Storage: Store below 30°C, in a cool, dry place, protected from light and moisture. Keep the sachets in the original outer pouch. Keep out of reach of children. Do not use after the expiry date printed on the pack.